Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Zymeworks Inc.
< Previous
1
2
3
Next >
Zymeworks Early R&D Day Highlights Progress in Development of Novel Pipeline Assets and Applications of Proprietary Next-Generation Technology Platforms
October 20, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks To Host Conference Call on Exclusive Licensing Agreement of Zanidatamab
October 19, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks to Host Third Quarter Results Conference Call
October 18, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Completes Plan to Become Delaware Corporation
October 13, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Announces Results of Special Meeting
October 07, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research & Development Day
October 03, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Independent Proxy Advisory Firm ISS Recommends a Vote FOR the Zymeworks Redomicile
September 26, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Independent Proxy Advisory Firm Glass Lewis Recommends Zymeworks Shareholders Vote FOR Redomicile
September 16, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) at European Society for Medical Oncology Annual Congress
September 12, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Announces Filing and Mailing of Materials for the Special Meeting to Approve Redomicile to Delaware
September 08, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers
September 04, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 04, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
August 01, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers at European Society for Medical Oncology (ESMO) Congress 2022 in Paris
July 25, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Reports Inducement Grant to New Chief Scientific Officer
July 22, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks to Host Second Quarter Results Conference Call
July 21, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Announces Plan to Become a Delaware Corporation
July 15, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer
June 27, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company
June 10, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Announces Participation in Upcoming Investor Conference
May 27, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2‑Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022
May 26, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal
May 20, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 04, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
May 02, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Confirms Receipt of Unsolicited, Non-Binding Proposal from All Blue Falcons
April 28, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract Cancer
April 28, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Announces Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks to Host First Quarter 2022 Results Conference Call
April 19, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
April 01, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results
February 24, 2022
From
Zymeworks Inc.
Via
Business Wire
Tickers
ZYME
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.